130 related articles for article (PubMed ID: 29424756)
1. Pazopanib-Associated Transient Ischemic Attack.
Revuelta-Herrero JL; Escudero-Vilaplana V; Álvarez-Álvarez R; Sanjurjo-Sáez M
Am J Ther; 2018; 25(3):e393-e394. PubMed ID: 29424756
[No Abstract] [Full Text] [Related]
2. Enterocolitis: An Unknown Side Effect of Pazopanib.
Sharma A; Masood U; Manocha D
Am J Ther; 2017; 24(4):e490-e491. PubMed ID: 27574944
[No Abstract] [Full Text] [Related]
3. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T
Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262
[No Abstract] [Full Text] [Related]
4. Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.
Hoashi T; Hirabayashi M; Nakajima R; Takahashi N; Saeki H
J Dermatol; 2017 Sep; 44(9):1078-1079. PubMed ID: 27726177
[No Abstract] [Full Text] [Related]
5. Angiosarcoma of the scalp successfully treated with pazopanib.
Tomita H; Koike Y; Asai M; Ogawa F; Abe K; Tanioka M; Utani A
J Am Acad Dermatol; 2014 Jan; 70(1):e19-21. PubMed ID: 24176520
[No Abstract] [Full Text] [Related]
6. Pazopanib: an alternative in taxane-resistant cutaneous angiosarcoma.
Fujita M; Endo Y; Fujisawa A; Tanioka M; Kabashima K; Miyachi Y
Eur J Dermatol; 2014; 24(2):267-8. PubMed ID: 24682601
[No Abstract] [Full Text] [Related]
7. [Atrial flutter probably related to pazopanib: A case report].
Puebla Villaescusa A; Díaz Gómez E; Salcedo Mingoarranz ÁL; Ramírez Cruz S; Hidalgo Correas FJ; García Díaz B
Farm Hosp; 2018 Jan; 42(1):33-34. PubMed ID: 29306315
[No Abstract] [Full Text] [Related]
8. Bronchopleural fistula arising after commencement of pazopanib for progressive sarcoma.
Cohen L; Neuhaus S; Chryssidis S; Kotasek D
ANZ J Surg; 2017 Jul; 87(7-8):E48-E49. PubMed ID: 25556827
[No Abstract] [Full Text] [Related]
9. Pazopanib can preserve cosmetic quality of life even in end-stage angiosarcoma.
Kitamura S; Hata H; Imafuku K; Haga N; Homma E; Shimizu H
Clin Exp Dermatol; 2015 Dec; 40(8):931-3. PubMed ID: 25817046
[No Abstract] [Full Text] [Related]
10. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer.
Kostaki M; Stathopoulou A; Plaka M; Zaras A; Chatzidimitriou E; Dimitrakopoulou A; Christofidou E; Polydorou D; Stratigos A
J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e361-e362. PubMed ID: 31066082
[No Abstract] [Full Text] [Related]
12. Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib.
Funatsu Y; Hirayama M; Shiraishi J; Asakura T; Wakaki M; Yamada E; Fujimoto K; Satomi R; Inaki S; Murata Y; Oyamada Y
Intern Med; 2016; 55(16):2197-202. PubMed ID: 27522994
[TBL] [Abstract][Full Text] [Related]
13. Response to pazopanib in two pediatric patients with pretreated relapsing synovial sarcoma.
Casanova M; Basso E; Magni C; Bergamaschi L; Chiaravalli S; Carta R; Tirtei E; Massimino M; Fagioli F; Ferrari A
Tumori; 2017 Jan; 103(1):e1-e3. PubMed ID: 27647230
[TBL] [Abstract][Full Text] [Related]
14. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
[TBL] [Abstract][Full Text] [Related]
15. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
16. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
17. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
18. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
